newsfilter
← Latest News
GlobeNewswire·

Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments

Reported Total DANYELZA net product revenues of $18.5 million for the third quarter of 2024Entered into exclusive license and distribution agreement with Nobelpharma for DANYELZA in Japan recognizing an upfront payment